Orexo initiates new study of OX640 in participants with allergic rhinitis [Yahoo! Finance]
OREXO AB SP/ADR (ORXOY)
NASDAQ:AMEX Investor Relations:
orexo.com/en/investors
Company Research
Source: Yahoo! Finance
OX640 is based on Orexo's proprietary drug delivery platform, AmorphOX ® , and has demonstrated positive data in a phase 1 clinical study in healthy volunteers. The new study will investigate the performance of OX640 in participants with allergic rhinitis. UPPSALA, Sweden Oct. 25, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the first participants have been dosed with OX640, an intranasal rescue medication for severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine, in a new study in subjects with allergic rhinitis (hay fever). The study will be completed during 2024 with results available early in 2025. Following the positive results from the phase 1 clinical study, OX640-001, where OX640 showed absorption of epinephrine and effects on blood pressure and heart rate equivalent to an epinephrine intramuscular auto-injector, Orexo now advances the development of OX640. In the new study, OX640-002, the epinephrine absorption
Show less
Read more
Impact Snapshot
Event Time:
ORXOY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORXOY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORXOY alerts
High impacting OREXO AB SP/ADR news events
Weekly update
A roundup of the hottest topics
ORXOY
News
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology [Yahoo! Finance]Yahoo! Finance
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyPR Newswire
- Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyPR Newswire
- Orexo initiates new study of OX640 in participants with allergic rhinitisPR Newswire
- Orexo initiates new study of OX640 in participants with allergic rhinitisPR Newswire